Over the past decade, antibodies that target immune inhibitory receptors such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed Death 1 (PD-1), and its ligand (PD-L1) have been extensively utilized in the field of cancer treatment. Here, CTLA4 is linked to cancer.